相关实验视频

Updated: May 5, 2026

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

药物先验痴呆症与勒维体的外周免疫特征

Tadashi Umehara¹, Masahiro Mimori², Tatsushi Kokubu³

¹Department of Neurology, The Jikei University School of Medicine, 3-19-18, Tokyo, 105-8471, Japan. tumety@jikei.ac.jp.

Journal of neurology

|April 6, 2024

概括

周围炎症与帕金森病 (PD) 和患有莱维体 (DLB) 的痴呆症有关. DLB患者的免疫细胞计数与对照人群不同,与疾病严重程度相关,这表明炎症在DLB病变发生过程中的作用.

科学领域:

神经免疫学神经免疫学
神经学神经学
免疫学免疫学免疫学

背景情况:

周围炎症越来越多地与神经退行性疾病的发病有关,包括帕金森病 (PD).
了解患有勒维体痴呆症 (DLB) 的免疫系统变化对于阐明疾病机制和潜在的治疗点至关重要.

研究的目的:

为了研究DLB的药物先验患者的外周免疫特征.
为了将这些免疫特征与PD患者和健康对照患者的免疫特征进行比较.
检查DLB和PD中外围免疫标记和临床特征之间的关联.

主要方法:

从93名参与者的外周血液分析:31名未使用药物的DLB,31名未使用药物的PD和31名对照.
测量绝对白细胞数量,白细胞亚群和炎症指数 (例如,中性粒细胞与淋巴细胞的比率).
评估与临床特征的关联,心脏交感性缩和条纹结合的I-FP-CIT.

主要成果:

与对照组相比,DLB患者的绝对淋巴细胞和基细胞数量较低.
在DLB中,较高的基细胞计数与更好的认知和运动功能相关,但与PD更为先进.
周围炎症指数与DLB和PD患者的较低体重指数有关.

结论:

在DLB中,外周免疫特征发生变化,类似于PD.
特定的免疫细胞计数和炎症标志物反映了DLB和PD的疾病进展.
这些发现有助于理解外周炎症在DLB病变发生中的作用.

关键词:

基细胞的数量.痴呆症与利维体的痴呆症.淋巴细胞的数量淋巴细胞的数量帕金森病是帕金森氏症的一种疾病.周围血液的炎症指数周边免疫细胞是周边免疫细胞.

更多相关视频

Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation

Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation

Published on: March 21, 2020

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

相关概念视频

Myasthenia Gravis: Diagnostic Tests

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...

Alzheimer Disease l: Introduction

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...

Alzheimer Disease ll: Pathophysiology

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...